Live News EQUITY M impact Jun 25, 2026, 12:30 AM UTC

HCM Presents Fanregratinib Data

HUTCHMED presents pivotal phase II data for fanregratinib in intrahepatic cholangiocarcinoma at ESMO Gastrointestinal Cancers Congress 2026

HCM

SQUAWKNEWS Updated Jun 25, 2026, 12:30 AM UTC

HCM - HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026